Krioglobulinemia – Rokowania, prognozy i postęp choroby

Krioglobulinemia
Rokowania, prognozy i postęp choroby

Rokowanie w krioglobulinemii jest złożone i zależy od typu krioglobulinemii, chorób współistniejących oraz odpowiedzi na leczenie. Wskaźnik przeżycia po 10 latach wynosi około 74%, z istotną różnicą między typem III (84%) a typem II (71%) (p=0,05). W przypadku krioglobulinemii związanej z HCV, zapalenie naczyń wiąże się z około 25% śmiertelnością w ciągu 5 lat, a rokowanie zależy od zajęcia nerek, OUN, serca i przewodu pokarmowego. Kluczowe czynniki prognostyczne to obecność chorób podstawowych (np. limfoproliferacyjnych, HBV, HCV), typ krioglobuliny, poziom krioprecypitatu, wielonarządowe zajęcie oraz stopień włóknienia wątroby. Zajęcie nerek znacząco pogarsza rokowanie, z 5-letnim przeżyciem powyżej 60% i 7-letnim około 30%, szczególnie w krioglobulinemii typu II związanej z HCV.

Krioglobulinemia – Rokowanie (przewidywanie wyniku)

Wskaźniki przeżycia w różnych typach krioglobulinemii
Czynniki wpływające na rokowanie
Rokowanie w zależności od zajęcia narządów
Predyktory nasilenia choroby
Czynniki związane z przetrwałą krioglobulinemią
Wpływ leczenia na rokowanie
Indywidualne czynniki rokownicze
Wnioski końcowe
Kolejne rozdziały

Krioglobulinemia – Rokowanie (przewidywanie wyniku)

Rokowanie w krioglobulinemii jest złożone i zależy od wielu czynników, w tym typu krioglobulinemii, chorób współistniejących oraz odpowiedzi na leczenie. Kluczowe znaczenie ma ocena stanu pacjenta z uwzględnieniem choroby podstawowej, aby dokładnie określić zasięg schorzenia.¹²

Wskaźniki przeżycia w różnych typach krioglobulinemii

Dane dotyczące długoterminowego przeżycia pacjentów z krioglobulinemią wskazują na istotne różnice między typami. Ogólny wskaźnik przeżycia po 10 latach wynosi około 74%, przy czym występuje statystycznie istotna różnica (p=0,05) między krioglobulinemią typu III (84%) a typu II (71%).³ Szacunki wskazują również, że wskaźnik przeżycia wynosi ogólnie około 70% po 10 latach od wystąpienia objawów i około 50% po 10 latach od diagnozy.⁴⁵

W przypadku krioglobulinemii związanej z HCV, zapalenie naczyń jest poważnym schorzeniem z około 25% śmiertelnością w ciągu 5 lat. Rokowanie w tej grupie, poza włóknieniem wątroby, zależy głównie od stanu nerek, ośrodkowego układu nerwowego, serca i przewodu pokarmowego, ponieważ naczynia krwionośne tych narządów są dotknięte chorobą.⁶

Czynniki wpływające na rokowanie

Rokowanie w krioglobulinemii zależy od kilku kluczowych czynników:

Obecność chorób podstawowych (np. zaburzenia limfoproliferacyjne, infekcja HBV lub HCV, choroby tkanki łącznej) – wszystkie zwiększają śmiertelność w porównaniu do zdrowej populacji⁷
Typ krioglobuliny (typ I lub mieszany)⁸
Poziom krioprecypitatu⁹
Zajęcie wielu narządów¹⁰
Stopień zaawansowania włóknienia wątroby, szczególnie w przypadkach związanych z HCV¹¹¹²
Odpowiedź na leczenie przeciwwirusowe¹³

Rokowanie w zależności od zajęcia narządów

Szczególnie istotne jest zajęcie określonych narządów, co znacząco wpływa na rokowanie:

Zajęcie nerek

Ogólne rokowanie jest gorsze u osób z współistniejącą chorobą nerek. Wskaźniki przeżycia u pacjentów z zajęciem nerek wahają się od ponad 60% przy 5-letniej obserwacji do 30% przy 7-letniej obserwacji. Ryzyko niewydolności nerek wydaje się być większe u pacjentów z chorobą związaną z HCV.¹⁴

Rokowanie w przypadku choroby nerek w częstszej krioglobulinemii typu II jest zróżnicowane. Większość pacjentów doświadcza powoli postępującego przebiegu z okresowymi zaostrzeniami, przy czym do jednej trzeciej pacjentów przechodzi pewien stopień remisji klinicznej. Badania prospektywne wykazały, że jedynie wiek (a nie parametry laboratoryjne) jest istotnym predyktorem śmiertelności w chorobie nerek związanej z krioglobulinemią typu II.¹⁵

Pacjenci z ciężkim zajęciem nerek po rocznej obserwacji częściej wymagają terapii nerkozastępczej (p<0,0001) i mają wyższy wskaźnik śmiertelności (p=0,02).¹⁶

Choroby limfoproliferacyjne

Choroby limfoproliferacyjne są częstsze u osób z krioglobulinemią. Pacjenci z krioglobulinemią mieszaną mogą rozwinąć łagodne nacieki limfoidalne w śledzionie i szpiku kostnym. Rzadziej u niektórych pacjentów może rozwinąć się chłoniak nieziarniczy z komórek B. Zgłaszana częstość występowania złośliwego chłoniaka w krioglobulinemii mieszanej waha się znacznie, od mniej niż 10% pacjentów do nawet 40%, z początkiem 5-10 lat po rozpoznaniu choroby.¹⁷

Predyktory nasilenia choroby

W badaniach zidentyfikowano kluczowe markery ciężkości u pacjentów z dodatnim krioglobulinami. Innowacyjnym wkładem jest opracowanie klinicznie stosowanego systemu oceny ciężkości, który integruje czynniki zidentyfikowane w analizie wieloczynnikowej:¹⁸

Plamica
Choroby hematologiczne
Objaw Raynauda
Podwyższony poziom krioglobulin

System ten wykazał lepszą dokładność predykcyjną w porównaniu do samych poziomów krioglobulin.¹⁹ Ponadto, najsilniejszym predyktorem związanym z krioglobulinemią był składnik C4 układu dopełniacza (χ²=55,344 i p<0,0001).²⁰

Czynniki związane z przetrwałą krioglobulinemią

U pacjentów z wirusowym zapaleniem wątroby typu C, przetrwała krioglobulinemia po leczeniu przeciwwirusowym wiąże się z zaawansowanym włóknieniem wątroby. W analizie wieloczynnikowej, zaawansowane włóknienie (iloraz szans [OR] 4,13, 95% przedział ufności [95% CI] 1,53-11,17, p=0,005) i liczba płytek krwi (OR 0,98, 95% CI 0,97-0,99, p=0,010) były niezależnie i istotnie związane z przetrwałą krioglobulinemią.²¹

Częstość występowania przetrwałej krioglobulinemii wynosi 34,5% po zakończeniu terapii przeciwwirusowej i jest związana z zaawansowanym włóknieniem, nawet po eliminacji HCV. Analiza regresji logistycznej wykazała, że przetrwała krioglobulinemia (OR 4,83, 95% CI 1,75-13,36, p=0,002) była istotnie związana z zaawansowanym włóknieniem u pacjentów z krioglobulinemią po terapii przeciwwirusowej.²²²³

Wpływ leczenia na rokowanie

Leczenie ma istotny wpływ na rokowanie u pacjentów z krioglobulinemią:

Leczenie przeciwwirusowe jest terapią z wyboru w przypadkach związanych z HCV. Badania wykazały lepsze przeżycie u pacjentów leczonych terapią przeciwwirusową (nawet u tych, którzy nie odpowiedzieli na leczenie lub u których doszło do nawrotu) w porównaniu z osobami poddanymi wyłącznie leczeniu immunosupresyjnemu.²⁴
Rituximab odgrywa kluczową rolę w leczeniu nawrotowej/opornej choroby, zastępując inne schematy immunosupresyjne. Ostatnie badania z przeciwciałem CD-20 (rituximab) wykazały korzystne wyniki i jego stosowanie jest coraz bardziej preferowane.²⁵²⁶
Całkowita lub częściowa remisja objawów zapalenia naczyń związanego z krioglobulinemią mieszaną, z wysokim, trwałym wskaźnikiem odpowiedzi wirusologicznej, została zgłoszona u ponad 80% pacjentów z przewlekłym zakażeniem HCV przyjmujących bezpośrednio działające leki przeciwwirusowe.²⁷

Indywidualne czynniki rokownicze

Rokowanie u konkretnego pacjenta zależy od kilku czynników indywidualnych, w tym:²⁸

Nasilenia choroby – u niektórych osób może nie występować żadne objawy lub mogą mieć bardzo łagodny przypadek niewymagający leczenia
Czasu diagnozy i rozpoczęcia leczenia – szybka diagnoza i leczenie mogą pomóc złagodzić objawy i zapobiec długoterminowym powikłaniom
Ewentualnego trwałego uszkodzenia narządów – jeśli nie doszło do trwałego uszkodzenia, rokowanie jest bardzo dobre

Warto podkreślić, że obecność krioglobulin we krwi sama w sobie nie wskazuje na wyższy wskaźnik śmiertelności – kluczowe znaczenie mają choroby współistniejące i ich nasilenie, a także skuteczność leczenia.²⁹

Wnioski końcowe

Na podstawie długoterminowej obserwacji pacjentów z krioglobulinemią można wyciągnąć trzy główne wnioski:³⁰

Kliniczne manifestacje zapalenia naczyń (skóra, nerki, nerwy) występują częściej w krioglobulinemii typu II niż typu III
Leczenie przeciwwirusowe jest terapią z wyboru, a rituximab odgrywa kluczową rolę w chorobie nawrotowej/opornej, zastępując inne schematy immunosupresyjne
Pomimo heterogeniczności klinicznych i laboratoryjnych aspektów choroby, krioglobulinemia typu II wykazuje gorszy wskaźnik przeżycia po 10 latach niż krioglobulinemia typu III

Wykrywanie krioglobulinemii w rutynowej diagnostyce laboratoryjnej jest wyzwaniem, ponieważ czynniki przedanalityczne odpowiadają za większość zmienności w badaniach. Dlatego do właściwego wspierania klinicystów w rutynowej praktyce należy stosować rygorystyczną fazę przedanalityczną oraz czułe i swoiste testy do dokładnego pomiaru krioglobulin.³¹

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

Materiały źródłowe

#1 Cryoglobulinemia – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK557606/
When assessing the prognosis of cryoglobulinemia, the patient’s underlying condition must be considered to determine the disease’s extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition. Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate. […] Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment. Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored. […] HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%. Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with HCV compared to mixed cryoglobulinemia.
#2 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
The prognosis in these patients depends on the presence of underlying diseases (eg, lymphoproliferative disorders, hepatitis B or C infection, connective-tissue disease), all of which increase the mortality rate over that of the healthy population and more accurately direct estimates of individual survival. For example, the prognosis in patients with chronic hepatitis C depends on their response to treatment; manifested by their decrease in viral load. Complete or partial remission of the manifestations of mixed cryoglobulinemic vasculitis, with high, sustained viral response rates, have been reported in more than 80% of patients with chronic HCV infection taking direct-acting viral agents. […] […] The overall prognosis is worse in persons with concomitant renal disease, lymphoproliferative disease, or plasma cell disorders. Mean survival is approximately 50% at 10 years after diagnosis. […]
#3 Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
https://pmc.ncbi.nlm.nih.gov/articles/PMC6023473/
The median age at diagnosis was 60 years (range 26-83). […] At 10 years, the overall survival rate was 71% in Type II MC and 84% in Type III (p 0.053). […] Overall survival rate at 10 years was 74%, with a significant difference (p 0.05) between Type III MC (84%) and Type II MC (71%). […] The finding of a better survival of the cases treated with antiviral therapy (even of non-responders or relapsed) as compared with those who underwent only immuno-suppressive treatments, does not mean that this therapy is useful independently of its outcome. […] In conclusion, from the long-term follow-up of our patients, three major considerations can be made: (1) Clinical manifestations of the vasculitis (skin, kidney, nerves) are more frequently in Type II MC than in Type III, (2) Antiviral treatment is the therapy of choice and rituximab plays a key role in the relapsed/refractory disease, replacing the other immuno-suppressive regimens, (3) Despite the heterogeneity of the clinical and laboratory aspects of the disease, Type II MC shows a poorer survival rate at 10 years than Type III MC.
#4 Cryoglobulinemia – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK557606/
When assessing the prognosis of cryoglobulinemia, the patient’s underlying condition must be considered to determine the disease’s extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition. Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate. […] Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment. Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored. […] HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%. Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with HCV compared to mixed cryoglobulinemia.
#5 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
The prognosis in these patients depends on the presence of underlying diseases (eg, lymphoproliferative disorders, hepatitis B or C infection, connective-tissue disease), all of which increase the mortality rate over that of the healthy population and more accurately direct estimates of individual survival. For example, the prognosis in patients with chronic hepatitis C depends on their response to treatment; manifested by their decrease in viral load. Complete or partial remission of the manifestations of mixed cryoglobulinemic vasculitis, with high, sustained viral response rates, have been reported in more than 80% of patients with chronic HCV infection taking direct-acting viral agents. […] […] The overall prognosis is worse in persons with concomitant renal disease, lymphoproliferative disease, or plasma cell disorders. Mean survival is approximately 50% at 10 years after diagnosis. […]
#6 Cryoglobulinemia – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK557606/
When assessing the prognosis of cryoglobulinemia, the patient’s underlying condition must be considered to determine the disease’s extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition. Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate. […] Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment. Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored. […] HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%. Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with HCV compared to mixed cryoglobulinemia.
#7 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
The prognosis in these patients depends on the presence of underlying diseases (eg, lymphoproliferative disorders, hepatitis B or C infection, connective-tissue disease), all of which increase the mortality rate over that of the healthy population and more accurately direct estimates of individual survival. For example, the prognosis in patients with chronic hepatitis C depends on their response to treatment; manifested by their decrease in viral load. Complete or partial remission of the manifestations of mixed cryoglobulinemic vasculitis, with high, sustained viral response rates, have been reported in more than 80% of patients with chronic HCV infection taking direct-acting viral agents. […] […] The overall prognosis is worse in persons with concomitant renal disease, lymphoproliferative disease, or plasma cell disorders. Mean survival is approximately 50% at 10 years after diagnosis. […]
#8 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#9 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#10 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#11 Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268180
Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. […] In multivariate analysis, advanced fibrosis (Odds Ratio [OR] 4.13, 95% Confidence Interval [95% CI] 1.5311.17, p = 0.005) and platelet counts (OR-0.98, 95% CI 0.970.99, p = 0.010) were independently and significantly associated with persistent cryoglobulinemia. […] The prevalence of the persistent cryoglobulinemia is 34.5% after completing antiviral therapy and it is associated with advanced fibrosis, also HCV clearance. […] The factors associated with the persistent cryoglobulinemia in SVR patients were advanced fibrosis (OR-1.93, 95% CI 1.023.65, p = 0.041) and platelet count (OR-0.98, 95% CI 0.960.99, p = 0.041) by multivariate analysis. […] Multivariate logistic regression analysis showed persistent (OR-4.83, 95% CI 1.7513.36, p = 0.002) was significantly associated with advanced fibrosis in patients with cryoglobulinemia follow up after antiviral therapy.
#12 Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268180
However advanced fibrosis has more influenced to persistent cryoglobulinemia than viral clearance. […] The association between hepatic necroinflammation and cryoglobulinemia was reported. […] Our study shows an independent association between persistent cryoprecipitate and advanced fibrosis. Cryoglobulinemia in SVR achieved patients after completion of antiviral therapy is associated with the advanced liver fibrosis.
#13 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
The prognosis in these patients depends on the presence of underlying diseases (eg, lymphoproliferative disorders, hepatitis B or C infection, connective-tissue disease), all of which increase the mortality rate over that of the healthy population and more accurately direct estimates of individual survival. For example, the prognosis in patients with chronic hepatitis C depends on their response to treatment; manifested by their decrease in viral load. Complete or partial remission of the manifestations of mixed cryoglobulinemic vasculitis, with high, sustained viral response rates, have been reported in more than 80% of patients with chronic HCV infection taking direct-acting viral agents. […] […] The overall prognosis is worse in persons with concomitant renal disease, lymphoproliferative disease, or plasma cell disorders. Mean survival is approximately 50% at 10 years after diagnosis. […]
#14 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
Survival rates reported among patients with kidney involvement vary from greater than 60% at 5 years of follow-up to 30% at 7 years of follow-up. The risk of kidney failure appears to be greater in those with HCV-associated disease. […] […] The prognosis of kidney disease in the more common type II cryoglobulinemia varies. Most patients experience a slowly progressive course punctuated by acute exacerbations, with up to one third of patients undergoing some degree of clinical remission. Bryce et al, in a prospective study, found only age (and no laboratory parameters) to be a significant predictor of mortality in type II cryoglobulinemic kidney disease. […] […] Lymphoproliferative disease is more common in individuals with cryoglobulinemia. Patients with mixed cryoglobulinemia may develop benign lymphoid infiltrates in the spleen and bone marrow. Less frequently, some patients develop B-cell non-Hodgkin lymphoma. The reported incidence of malignant lymphoma in mixed cryoglobulinemia varies widely, from less than 10% of patients to as high as 40%, with onset 5-10 years after disease diagnosis.
#15 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
Survival rates reported among patients with kidney involvement vary from greater than 60% at 5 years of follow-up to 30% at 7 years of follow-up. The risk of kidney failure appears to be greater in those with HCV-associated disease. […] […] The prognosis of kidney disease in the more common type II cryoglobulinemia varies. Most patients experience a slowly progressive course punctuated by acute exacerbations, with up to one third of patients undergoing some degree of clinical remission. Bryce et al, in a prospective study, found only age (and no laboratory parameters) to be a significant predictor of mortality in type II cryoglobulinemic kidney disease. […] […] Lymphoproliferative disease is more common in individuals with cryoglobulinemia. Patients with mixed cryoglobulinemia may develop benign lymphoid infiltrates in the spleen and bone marrow. Less frequently, some patients develop B-cell non-Hodgkin lymphoma. The reported incidence of malignant lymphoma in mixed cryoglobulinemia varies widely, from less than 10% of patients to as high as 40%, with onset 5-10 years after disease diagnosis.
#16 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#17 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
Survival rates reported among patients with kidney involvement vary from greater than 60% at 5 years of follow-up to 30% at 7 years of follow-up. The risk of kidney failure appears to be greater in those with HCV-associated disease. […] […] The prognosis of kidney disease in the more common type II cryoglobulinemia varies. Most patients experience a slowly progressive course punctuated by acute exacerbations, with up to one third of patients undergoing some degree of clinical remission. Bryce et al, in a prospective study, found only age (and no laboratory parameters) to be a significant predictor of mortality in type II cryoglobulinemic kidney disease. […] […] Lymphoproliferative disease is more common in individuals with cryoglobulinemia. Patients with mixed cryoglobulinemia may develop benign lymphoid infiltrates in the spleen and bone marrow. Less frequently, some patients develop B-cell non-Hodgkin lymphoma. The reported incidence of malignant lymphoma in mixed cryoglobulinemia varies widely, from less than 10% of patients to as high as 40%, with onset 5-10 years after disease diagnosis.
#18 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#19 Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis
https://www.mdpi.com/2077-0383/14/2/556
Identification of Key Predictors of Cryoglobulinemia Severity at Diagnosis: Threshold, Type, and Severity Score at Diagnosis […] Background: Cryoglobulinemia (CG) syndrome is a heterogeneous condition characterized by the presence of cryoglobulins in serum, often leading to vasculitis with protean clinical manifestations. Understanding the presentation of cryoglobulinemia-related symptoms based on cryoprecipitate levels, GC type, and severity at diagnosis is essential for effective management. Hence, this study aimed to provide a comprehensive analysis of patients with positive cryoglobulin detection to investigate these aspects. […] At the end of the one-year follow-up, they required frequent renal replacement therapy (p < 0.0001) and had a higher mortality rate (p = 0.02). [...] This study identifies severity markers in patients with positive cryoprecipitate and proposes a score related to severity at diagnosis. [...] Factors influencing disease severity include the type of cryoglobulin (type I or mixed), cryoprecipitate levels, the presence of underlying conditions (e.g., hematological malignancy, autoimmune disorders, chronic infection), and multi-organ involvement. [...] The studyâs most innovative contribution is the development of a clinically applicable severity scoring system. Integrating factors identified through multivariate analysisâpurpura, hematological conditions, Raynaudâs phenomenon, and elevated cryoprecipitate levelsâdemonstrated superior predictive accuracy compared to cryoprecipitate levels alone. [...] In conclusion, cryoglobulinemic vasculitis must be considered independently of the cryoprecipitate threshold and type. Moreover, a novel severity scoring system based on four items (purpura, Raynaudâs phenomenon, hematological conditions, and cryoprecipitate) may predict severity and clinical decision-making and patient care.
#20
https://link.springer.com/article/10.1007/s12026-023-09434-9
The presence of CG i.e., cryoglobulinemia – may be transient (e.g., after acute infection) or persistent and asymptomatic, or may lead to symptoms and signs of immune complex vasculitis. […] The predictor most strongly associated with cryoglobulinemia was C4 (2=55.344 and p0.0001). […] The overall accuracy of our CHAID decision tree model for predicting cryoglobulinemia was 82.9%. Specifically, 97.5% of patients were correctly classified as negative and only 30.4% of patients were correctly classified as positive. […] In summary, the detection of CG in routine laboratory medicine is challenging because preanalytical factors account for most of the variability in assays. Therefore, the rigorous preanalytical phase and sensitive and specific assays for accurate CG measurement should be used in routine practice to adequately assist clinicians.
#21 Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268180
Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. […] In multivariate analysis, advanced fibrosis (Odds Ratio [OR] 4.13, 95% Confidence Interval [95% CI] 1.5311.17, p = 0.005) and platelet counts (OR-0.98, 95% CI 0.970.99, p = 0.010) were independently and significantly associated with persistent cryoglobulinemia. […] The prevalence of the persistent cryoglobulinemia is 34.5% after completing antiviral therapy and it is associated with advanced fibrosis, also HCV clearance. […] The factors associated with the persistent cryoglobulinemia in SVR patients were advanced fibrosis (OR-1.93, 95% CI 1.023.65, p = 0.041) and platelet count (OR-0.98, 95% CI 0.960.99, p = 0.041) by multivariate analysis. […] Multivariate logistic regression analysis showed persistent (OR-4.83, 95% CI 1.7513.36, p = 0.002) was significantly associated with advanced fibrosis in patients with cryoglobulinemia follow up after antiviral therapy.
#22 Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268180
Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. […] In multivariate analysis, advanced fibrosis (Odds Ratio [OR] 4.13, 95% Confidence Interval [95% CI] 1.5311.17, p = 0.005) and platelet counts (OR-0.98, 95% CI 0.970.99, p = 0.010) were independently and significantly associated with persistent cryoglobulinemia. […] The prevalence of the persistent cryoglobulinemia is 34.5% after completing antiviral therapy and it is associated with advanced fibrosis, also HCV clearance. […] The factors associated with the persistent cryoglobulinemia in SVR patients were advanced fibrosis (OR-1.93, 95% CI 1.023.65, p = 0.041) and platelet count (OR-0.98, 95% CI 0.960.99, p = 0.041) by multivariate analysis. […] Multivariate logistic regression analysis showed persistent (OR-4.83, 95% CI 1.7513.36, p = 0.002) was significantly associated with advanced fibrosis in patients with cryoglobulinemia follow up after antiviral therapy.
#23 Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients | PLOS One
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268180
However advanced fibrosis has more influenced to persistent cryoglobulinemia than viral clearance. […] The association between hepatic necroinflammation and cryoglobulinemia was reported. […] Our study shows an independent association between persistent cryoprecipitate and advanced fibrosis. Cryoglobulinemia in SVR achieved patients after completion of antiviral therapy is associated with the advanced liver fibrosis.
#24 Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
https://pmc.ncbi.nlm.nih.gov/articles/PMC6023473/
The median age at diagnosis was 60 years (range 26-83). […] At 10 years, the overall survival rate was 71% in Type II MC and 84% in Type III (p 0.053). […] Overall survival rate at 10 years was 74%, with a significant difference (p 0.05) between Type III MC (84%) and Type II MC (71%). […] The finding of a better survival of the cases treated with antiviral therapy (even of non-responders or relapsed) as compared with those who underwent only immuno-suppressive treatments, does not mean that this therapy is useful independently of its outcome. […] In conclusion, from the long-term follow-up of our patients, three major considerations can be made: (1) Clinical manifestations of the vasculitis (skin, kidney, nerves) are more frequently in Type II MC than in Type III, (2) Antiviral treatment is the therapy of choice and rituximab plays a key role in the relapsed/refractory disease, replacing the other immuno-suppressive regimens, (3) Despite the heterogeneity of the clinical and laboratory aspects of the disease, Type II MC shows a poorer survival rate at 10 years than Type III MC.
#25 Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
https://pmc.ncbi.nlm.nih.gov/articles/PMC6023473/
The median age at diagnosis was 60 years (range 26-83). […] At 10 years, the overall survival rate was 71% in Type II MC and 84% in Type III (p 0.053). […] Overall survival rate at 10 years was 74%, with a significant difference (p 0.05) between Type III MC (84%) and Type II MC (71%). […] The finding of a better survival of the cases treated with antiviral therapy (even of non-responders or relapsed) as compared with those who underwent only immuno-suppressive treatments, does not mean that this therapy is useful independently of its outcome. […] In conclusion, from the long-term follow-up of our patients, three major considerations can be made: (1) Clinical manifestations of the vasculitis (skin, kidney, nerves) are more frequently in Type II MC than in Type III, (2) Antiviral treatment is the therapy of choice and rituximab plays a key role in the relapsed/refractory disease, replacing the other immuno-suppressive regimens, (3) Despite the heterogeneity of the clinical and laboratory aspects of the disease, Type II MC shows a poorer survival rate at 10 years than Type III MC.
#26 Cryoglobulinemia – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK557606/
When assessing the prognosis of cryoglobulinemia, the patient’s underlying condition must be considered to determine the disease’s extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition. Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate. […] Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment. Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored. […] HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%. Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with HCV compared to mixed cryoglobulinemia.
#27 Cryoglobulinemia: Practice Essentials, Pathophysiology, Etiology
https://emedicine.medscape.com/article/329255-overview
The prognosis in these patients depends on the presence of underlying diseases (eg, lymphoproliferative disorders, hepatitis B or C infection, connective-tissue disease), all of which increase the mortality rate over that of the healthy population and more accurately direct estimates of individual survival. For example, the prognosis in patients with chronic hepatitis C depends on their response to treatment; manifested by their decrease in viral load. Complete or partial remission of the manifestations of mixed cryoglobulinemic vasculitis, with high, sustained viral response rates, have been reported in more than 80% of patients with chronic HCV infection taking direct-acting viral agents. […] […] The overall prognosis is worse in persons with concomitant renal disease, lymphoproliferative disease, or plasma cell disorders. Mean survival is approximately 50% at 10 years after diagnosis. […]
#28 Cryoglobulinemia: Symptoms & Treatment
https://my.clevelandclinic.org/health/diseases/13204-cryoglobulinemia
Your prognosis depends on several factors, including: […] In addition, the severity of the condition varies. Some people dont have any symptoms or have a very mild case that doesnt require treatment. For people with moderate to severe cases, prompt diagnosis and treatment can help relieve symptoms and prevent long-term complications. If you havent experienced any permanent damage to your organs, your prognosis is very good.
#29 Cryoglobulinemia – StatPearls – NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK557606/
When assessing the prognosis of cryoglobulinemia, the patient’s underlying condition must be considered to determine the disease’s extent accurately. Specifically, when considering type 1 cryoglobulinemia, hematologic diseases are often a preexisting condition. Studies have shown that the presence of cryoglobulins in the blood does not indicate a higher mortality rate. […] Survival rates with cryoglobulinemia are 70% after 10 years of evident symptoms and approximately 50% 10 years after diagnosis. The prognosis largely depends on comorbidities and their severity, as well as the effectiveness of treatment. Recent trials with the CD-20 antibody rituximab have shown some beneficial results, and its use is being favored. […] HCV-related cryoglobulinemia vasculitis is a significant disease with an approximate 5-year mortality rate of 25%. Prognosis, aside from liver fibrosis, usually depends on the status of the kidneys, CNS, heart, and gastrointestinal tract. The vascularity associated with these organs is affected and contributes heavily to the prognosis. Renal failure is shown to be higher in those with HCV compared to mixed cryoglobulinemia.
#30 Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
https://pmc.ncbi.nlm.nih.gov/articles/PMC6023473/
The median age at diagnosis was 60 years (range 26-83). […] At 10 years, the overall survival rate was 71% in Type II MC and 84% in Type III (p 0.053). […] Overall survival rate at 10 years was 74%, with a significant difference (p 0.05) between Type III MC (84%) and Type II MC (71%). […] The finding of a better survival of the cases treated with antiviral therapy (even of non-responders or relapsed) as compared with those who underwent only immuno-suppressive treatments, does not mean that this therapy is useful independently of its outcome. […] In conclusion, from the long-term follow-up of our patients, three major considerations can be made: (1) Clinical manifestations of the vasculitis (skin, kidney, nerves) are more frequently in Type II MC than in Type III, (2) Antiviral treatment is the therapy of choice and rituximab plays a key role in the relapsed/refractory disease, replacing the other immuno-suppressive regimens, (3) Despite the heterogeneity of the clinical and laboratory aspects of the disease, Type II MC shows a poorer survival rate at 10 years than Type III MC.
#31
https://link.springer.com/article/10.1007/s12026-023-09434-9
The presence of CG i.e., cryoglobulinemia – may be transient (e.g., after acute infection) or persistent and asymptomatic, or may lead to symptoms and signs of immune complex vasculitis. […] The predictor most strongly associated with cryoglobulinemia was C4 (2=55.344 and p0.0001). […] The overall accuracy of our CHAID decision tree model for predicting cryoglobulinemia was 82.9%. Specifically, 97.5% of patients were correctly classified as negative and only 30.4% of patients were correctly classified as positive. […] In summary, the detection of CG in routine laboratory medicine is challenging because preanalytical factors account for most of the variability in assays. Therefore, the rigorous preanalytical phase and sensitive and specific assays for accurate CG measurement should be used in routine practice to adequately assist clinicians.